Loading…
Hyderabad generic drugmaker and API producer, one of India's largest exporters of generic formulations to the US and Europe.
Hyderabad generic drugmaker and API producer, one of India's largest exporters of generic formulations to the US and Europe.
Makes the active ingredient as well as the finished tablet, so it can sell ingredients to others and still capture the margin on its own generics. The US is the largest market. The founding Reddy family remains the main shareholder.
In one line: A generics-only, API-integrated Teva.
Moat: narrow (scale, cost advantage, regulatory licence). Vertically integrated API-to-formulation scale gives a cost edge in commodity generics.
Headquarters: Hyderabad, India · Founded: 1986 · Employees: 46,455
Size Aurobindo Pharma (AUROPHARMA.NS) is an India Health Care company (Pharmaceuticals: Other) with a market value of $10.9B, the 112th largest of 1,058 India companies the cockpit tracks. Shares closed at ₹1,800 on 6 Nov 2026.
Performance Over six months the shares gained 21.7%, against -6.7% for the median peer and 0.0% for the India market (cap-weighted) — 4th highest of 11 in its peer set.
Growth Revenue grew 13.5% over the last twelve months (peer median +9.1%); the operating margin is 15.3% (peer median 22.4%).
Valuation It trades at 22.4× forward earnings against a peer median of 18.1× (3rd most expensive of 8).
Price implies For today's price to make sense, revenue must grow about 21% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is +15 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 1.9 points below its cost of capital (13.0% WACC).
Next results Next results expected around 14 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹369B | ₹334B | ₹314B | ₹287B | ₹246B |
| Revenue growth | — | +6% | +9% | +17% | — |
| Gross profit | ₹146B | ₹106B | ₹93.8B | ₹81.4B | ₹69.0B |
| EBITDA | ₹76.1B | ₹74.7B | ₹64.5B | ₹57.1B | ₹38.2B |
| Net income | ₹39.9B | ₹35.0B | ₹34.9B | ₹31.7B | ₹19.3B |
| Free cash flow | n/a | ₹28.3B | ₹18.8B | -₹11.0B | ₹184M |
| Capital expenditure | n/a | ₹31.0B | ₹25.2B | ₹35.6B | ₹27.2B |
| Total debt | ₹86.3B | ₹80.7B | ₹82.6B | ₹66.5B | ₹52.9B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Aurobindo Pharma AUROPHARMA.NS | $10.9B | +22% | +14% | 15% | 22.4× | 21.0% |
| Sun Pharmaceutical Industries SUNPHARMA.NS | $47.3B | +1% | +12% | 23% | 35.4× | 28.4% |
| Cipla CIPLA.NS | $12.1B | +4% | -1% | 13% | 29.0× | 28.2% |
| Dr. Reddy's Laboratories DRREDDY.NS | $12.1B | +5% | -4% | 9% | 31.8× | 30.1% |
| Teva Pharmaceutical Industries Limited Sponsored ADR TEVA | $49.7B | +19% | -4% | 19% | 15.1× | 10.2% |
| Sandoz SDZ.SW | $44.4B | +24% | +1% | 15% | 25.3× | 7.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | AUROPHARMA.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +7.0% | +3.2% | 4th highest of 11 |
| 6-month return | +21.7% | -6.7% | 4th highest of 11 |
| Distance from 52-week high | -0.3% | -21.8% | highest of 11 |
| Revenue growth (TTM) | +13.5% | +9.1% | 3rd highest of 9 |
| Operating margin | 15.3% | 22.4% | 4th lowest of 9 |
| Forward P/E | 22.4× | 18.1× | 3rd most expensive of 8 |
| Growth the price implies (Req g, 7 yrs) | 21.0% | 1.0% | 3rd most demanding of 9 |
| Growth delivered (Del g) | +6.3% | +7.0% | 5th highest of 9 |
| Hurdle (Req g minus delivered) | +14.6 pp | -2.6 pp | 3rd most demanding of 9 |
| ROIC minus cost of capital | -1.9 pp | +9.1 pp | 3rd lowest of 9 |
| EV / EBITDA | 13.4× | 10.2× | 2nd most expensive of 4 |
| Net debt / EBITDA | -0.2× | -0.1× | 2nd least indebted of 4 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Aurobindo Pharma AUROPHARMA.NS | India | $10.9B | +22% | +14% | 15% | 22.4× | 21.0% | +6.3% |
| Cipla CIPLA.NS | India | $12.1B | +4% | -1% | 13% | 29.0× | 28.2% | +8.1% |
| Zhejiang NHU 002001.SZ | China | $12.3B | -23% | +11% | 33% | 9.9× | -7.8% | +16.7% |
| Lupin LUPIN.NS | India | $9.65B | -19% | +24% | 24% | 20.9× | 8.8% | +13.0% |
| Abivax ABVX.PA | France | $7.58B | -25% | n/a | n/a | n/a | n/a | n/a |
| Dong-E-E-Jiao 000423.SZ | China | $4.80B | -8% | +8% | 29% | 17.1× | -4.6% | +14.5% |
| Shijiazhuang Yiling Pharmaceutical 002603.SZ | China | $4.02B | -6% | +32% | 21% | 18.1× | -3.2% | -2.2% |
| Guangdong Zhongsheng Pharmaceutical 002317.SZ | China | $3.13B | +35% | -14% | 9% | 80.3× | 34.7% | +5.9% |
| Bausch Health Companies BHC.TO | Canada | $3.09B | +48% | +10% | 27% | 1.9× | -14.5% | +5.9% |
| Jilin Aodong Pharmaceutical 000623.SZ | China | $3.02B | -9% | -4% | -13% | n/a | 5.2% | +1.0% |
| Revolution Medicines RVMD | United States | $41.2B | +36% | n/a | n/a | n/a | n/a | n/a |